GHRP-6: What It Is and How It Works

GHRP-6 — Growth Hormone Releasing Peptide-6 — is a synthetic hexapeptide that binds the GHS-R1a receptor, also known as the ghrelin receptor, and stimulates the release of growth hormone from the anterior pituitary. Its six-amino-acid sequence is His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, molecular formula C₄₆H₅₆N₁₂O₆, molecular weight approximately 873 g/mol. Cyril Bowers's group synthesized it in the early 1980s, and it became one of the most studied peptide secretagogues in experimental endocrinology over the following four decades.

The chemical structure of GHRP-6

The numeral in the name is direct: the peptide has six amino acids. Two of those six residues are in the D-configuration — the mirror-image, non-natural form: D-Trp at position 2 and D-Phe at position 5. Incorporating D-amino acids into a synthetic peptide is a deliberate design choice rather than an artifact of the synthesis. Proteases — the enzymes responsible for breaking down peptide chains — degrade D-amino acids more slowly than their naturally occurring L-counterparts. That resistance extends the compound's half-life in experimental biological systems, making GHRP-6 a more tractable research tool than a peptide of equivalent length composed entirely of natural residues.

The carboxyl terminus carries an amide group (NH₂) rather than a free carboxylic acid. C-terminal amidation is a second stability-enhancing modification: it further reduces metabolic degradation in experimental models. Both the D-amino acid substitutions and the C-terminal amide are features of design, not incidental consequences of the synthesis route.

The GHS-R1a receptor

For years, researchers knew that synthetic secretagogues like GHRP-6 acted on a specific receptor, but its molecular identity remained unresolved. In 1996, Andrew Howard and colleagues at Merck cloned and identified GHS-R1a — Growth Hormone Secretagogue Receptor type 1a. The work was published in *Science* and established the molecular framework for understanding how synthetic secretagogues function (Howard AD et al., Science, 1996, PMID 8895091).

GHS-R1a is a G-protein-coupled receptor expressed primarily in two tissues: the somatotrophs of the anterior pituitary — the cells that produce and release GH — and in hypothalamic neurons. When GHRP-6 binds the receptor, it activates intracellular calcium mobilization and protein kinase C. Those signaling cascades drive exocytosis of GH-containing vesicles.

Three years after GHS-R1a was identified, Kojima and colleagues identified ghrelin — an acylated peptide produced predominantly in the stomach — as the endogenous natural ligand for that same receptor (Kojima M et al., Nature, 1999, PMID 10604470). That finding changed how the GHRP-6 literature was read: the synthetic peptide acts on the same receptor as the endogenous hormone that signals hunger and regulates energy balance.

How GHRP-6 stimulates growth hormone release

The published literature describes two complementary pathways for GHRP-6's action on the GH axis:

• Direct pituitary action: GHRP-6 binds GHS-R1a on somatotrophs and triggers GH secretion independently, without requiring concurrent hypothalamic input.
• Hypothalamic action: GHRP-6 increases GHRH release from the hypothalamus and simultaneously suppresses somatostatin, the endogenous inhibitor of GH secretion. Both effects together amplify the resulting GH pulse.

The combination of these two pathways produces GH pulses of greater amplitude than those observed with GHRH alone under equivalent experimental conditions. That characteristic led multiple research groups to investigate co-administration of GHRP-6 with GHRH analogues in animal models and in endocrine physiology studies in healthy volunteers, aiming to characterize the interaction between the two stimulatory pathways.

GHRP-6 and ghrelin: the same receptor, two molecules

GHRP-6 was developed more than fifteen years before ghrelin was discovered. The shared receptor — confirmed in 1999 — turned GHRP-6 into a reference tool for investigating the ghrelin/GHS-R1a axis, a system whose biology extends well beyond GH secretion.

Ghrelin regulates gastric emptying, modulates reward circuitry and energy homeostasis signaling, and has documented effects in cardiovascular stress models. Because GHRP-6 activates the same receptor, it has also been studied in the context of those secondary functions. Most work aimed at isolating those effects has used ghrelin itself or more selective analogues, since they separate the mechanisms more cleanly, but GHRP-6 remains the standard reference for GHS-R1a agonism in the broad sense.

One of the most consistently reproduced effects of GHRP-6 in animal models is appetite stimulation. Activation of GHS-R1a in those models produces a reliable increase in food intake — the same orexigenic response as endogenous ghrelin — confirming that both molecules engage the same downstream signaling system.

Comparison with other secretagogues and GHRH analogues

GHRP-6 is not the only research compound that acts on GHS-R1a. Ipamorelin is another secretagogue in the same family, with a different selectivity profile. Published studies show that ipamorelin stimulates GH secretion without the effects on cortisol, prolactin, and ACTH that are recorded with GHRP-6. Researchers designing experiments that aim to isolate the effect on GH tend to prefer ipamorelin for that purpose; GHRP-6 is used when the interest lies in GHS-R1a agonism more broadly.

Sermorelin and CJC-1295 without DAC belong to a different class: they are GHRH analogues and act through the GHRH receptor, not GHS-R1a. Research designs that seek a more pronounced stimulation of GH secretion frequently combine a GHRP with a GHRH analogue. The two pathways are synergistic — a GHRP amplifies the response to GHRH and vice versa — enabling researchers to study the interaction between the two stimulatory systems under controlled conditions.

Laboratory research use only

The GHRP-6 supplied by PeptoClinic is Research Use Only (RUO) material, intended for in vitro synthesis and laboratory research. It is not a medicine, not a dietary supplement, and has not been evaluated or approved by any regulatory authority — including the FDA, ANMAT, or any equivalent — for use in humans or animals.

PeptoClinic does not provide administration protocols, dosing guidance, or clinical use instructions. Requests that involve guidance for human use are declined.

Every lot ships with the certificate of analysis from the independent analytical laboratory that verified the compound's purity and identity. The purity specification for research peptides in the PeptoClinic catalogue is ≥99% by HPLC. Details of the documentation and verification process are on the quality page.

Requesting a quote for GHRP-6

PeptoClinic does not publish prices. The process begins when a researcher describes the compound, the required purity specification, the quantity, and the destination. The technical team reviews the logistics route and the available documentation and returns a written quote, normally within one business day. PeptoClinic ships to destinations across the Americas; cold-chain routing and customs documentation details are on the shipping page.